Baidu
map

CIRC RES:目前很大法洛氏四联症队列的全外显子测序研究

2018-12-01 MedSci MedSci原创

罕见的遗传变异在先天性心脏病的发生中起到重要作用,但目前尚缺乏对散发性法洛氏四联症(TOF)的大型遗传研究。本研究的目的旨在通过全外显子测序(WES)对一个目前最大的散发性TOF队列进行遗传变异的研究。本研究对829名散发性TOF患者进行了WES测序,分析结果显示,NOTCH1 基因是最常见的变异基因,共在37个先证者中发现了31处变异(4.5%; 95% [CI]:3.2-6.1%),包括7个功

罕见的遗传变异在先天性心脏病的发生中起到重要作用,但目前尚缺乏对散发性法洛氏四联症(TOF)的大型遗传研究。本研究的目的旨在通过全外显子测序(WES)对一个目前最大的散发性TOF队列进行遗传变异的研究。

本研究对829名散发性TOF患者进行了WES测序,分析结果显示,NOTCH1 基因是最常见的变异基因,共在37个先证者中发现了31处变异(4.5%; 95% [CI]:3.2-6.1%),包括7个功能缺失突变和22个错义突变,并对三个突变(p.G200R, p.C607Y 和p.N1875S)进行了功能验证,发现其中2个突变降低了Jagged1-NOTCH1信号通路的活性。其次,在2.4%的患者中发现了FLT4 基因的突变,在21名患者中发现了22处有害突变。另外,除了NOTCH1 、FLT4 和已知的TBX1基因,本研究还筛选出了其他几个候选基因:RYR1, ZFPM1, CAMTA2, DLX6 和 PCM1。

研究结果显示,NOTCH1 基因是散发性法洛氏四联症最常见的变异基因,其次是FLT4 基因。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1949434, encodeId=742d1949434eb, content=<a href='/topic/show?id=7ba66486882' target=_blank style='color:#2F92EE;'>#法洛氏四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64868, encryptionId=7ba66486882, topicName=法洛氏四联症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 27 23:56:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986796, encodeId=9f721986e96b8, content=<a href='/topic/show?id=537229409eb' target=_blank style='color:#2F92EE;'>#全外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29409, encryptionId=537229409eb, topicName=全外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Oct 14 10:56:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556318, encodeId=df5e155631879, content=<a href='/topic/show?id=17d742864ea' target=_blank style='color:#2F92EE;'>#外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42864, encryptionId=17d742864ea, topicName=外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee014741656, createdName=jinweidong, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619050, encodeId=130016190505e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1949434, encodeId=742d1949434eb, content=<a href='/topic/show?id=7ba66486882' target=_blank style='color:#2F92EE;'>#法洛氏四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64868, encryptionId=7ba66486882, topicName=法洛氏四联症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 27 23:56:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986796, encodeId=9f721986e96b8, content=<a href='/topic/show?id=537229409eb' target=_blank style='color:#2F92EE;'>#全外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29409, encryptionId=537229409eb, topicName=全外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Oct 14 10:56:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556318, encodeId=df5e155631879, content=<a href='/topic/show?id=17d742864ea' target=_blank style='color:#2F92EE;'>#外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42864, encryptionId=17d742864ea, topicName=外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee014741656, createdName=jinweidong, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619050, encodeId=130016190505e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1949434, encodeId=742d1949434eb, content=<a href='/topic/show?id=7ba66486882' target=_blank style='color:#2F92EE;'>#法洛氏四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64868, encryptionId=7ba66486882, topicName=法洛氏四联症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 27 23:56:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986796, encodeId=9f721986e96b8, content=<a href='/topic/show?id=537229409eb' target=_blank style='color:#2F92EE;'>#全外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29409, encryptionId=537229409eb, topicName=全外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Oct 14 10:56:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556318, encodeId=df5e155631879, content=<a href='/topic/show?id=17d742864ea' target=_blank style='color:#2F92EE;'>#外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42864, encryptionId=17d742864ea, topicName=外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee014741656, createdName=jinweidong, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619050, encodeId=130016190505e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1949434, encodeId=742d1949434eb, content=<a href='/topic/show?id=7ba66486882' target=_blank style='color:#2F92EE;'>#法洛氏四联症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64868, encryptionId=7ba66486882, topicName=法洛氏四联症)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=yeye5224612, createdTime=Fri Sep 27 23:56:00 CST 2019, time=2019-09-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1986796, encodeId=9f721986e96b8, content=<a href='/topic/show?id=537229409eb' target=_blank style='color:#2F92EE;'>#全外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=29409, encryptionId=537229409eb, topicName=全外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Mon Oct 14 10:56:00 CST 2019, time=2019-10-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556318, encodeId=df5e155631879, content=<a href='/topic/show?id=17d742864ea' target=_blank style='color:#2F92EE;'>#外显子测序#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42864, encryptionId=17d742864ea, topicName=外显子测序)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=3ee014741656, createdName=jinweidong, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1619050, encodeId=130016190505e, content=<a href='/topic/show?id=492a42862bd' target=_blank style='color:#2F92EE;'>#外显子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=42862, encryptionId=492a42862bd, topicName=外显子)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Mon Dec 03 12:56:00 CST 2018, time=2018-12-03, status=1, ipAttribution=)]

相关资讯

盘点:JACC十一月第四期研究一览

1.NT-proBNP指导下的心衰治疗花费更多且无益处DOI: 10.1016/j.jacc.2018.08.2184http://www.onlinejacc.org/content/72/21/2551GUIDE-IT临床试验比较了N-末端B型利钠肽(NT-proBNP)指导下的心衰治疗和单纯的内科治疗在高风险心衰患者中的效果,但该研究因无明显作用而被提前终止。本研究的目的旨在评估GUID

JAHA:房颤负荷与活动量呈负相关性

近期有研究显示房颤患者的活动量与心血管死亡和发病风险呈相关性。本研究的目的旨在评估房颤的日负荷对接受肺静脉隔离患者活动量的影响。本研究纳入了DISCERN AF临床研究中的对象,所有对象均有心脏监测仪记录每天的房性心动过速和房颤(AT/AF)与相应的活动量水平。最终纳入分析了50例患者,每例患者平均有887次记录。结果显示,消融后的每日AT/AF范围为0-1440min,每日活动量的最小时间和最大

JAHA:血栓闭塞性脉管炎的远期预后及影响因素

目前,尚缺乏血栓闭塞性脉管炎的远期预后资料,本研究的目的旨在评估血栓闭塞性脉管炎的远期预后和影响预后的因素。本研究纳入分析了224名血栓闭塞性脉管炎患者,并对血管事件和截肢相关危险因素进行了分析。患者的平均诊断年龄为38.5 (32–46)岁,女性占23.8%,白种人占81.7%。经过平均5.7年时间的随访,有58.9%的患者发生血管疾病,21.4%的患者接受了截肢,1.4%的患者死亡。无血管疾病

JACC:Brugada 综合征患者常同时存在结构和电生理的异常

Brugada 综合征(Brs)结构畸形的发病率和临床特点尚不清楚。本研究的目的旨在探究Brs患者的遗传背景、电解剖异常和病理基础间的相关性。剖学单极和双极性标测指导下的右室流出道心内膜心肌的活检,并对所有的患者进行了遗传学分析。结果发现,在93%的单极检测患者和50%双极检测患者中检测出了低电压区域(LVAs),且单极的LVAs往往大于双极检测的。10例患者中检测出了致病性的基因突变,在75%的

JACC:FFR指导下的冠脉搭桥预后和血管造影指导下的比较

分数流量储备(FFR)在评估冠脉搭桥术中的冠脉狭窄的作用尚不清楚,本研究的目的旨在比较和评估FFR指导下的冠脉搭桥术和血管造影指导下的冠脉搭桥术的临床预后。本研究纳入分析了100例冠脉搭桥的患者,随机分至FFR指导组和血管造影组,主要终点事件是术后6个月移植失败的百分比。术后6个月,共有72名患者的冠脉血管造影资料是完整的,FFR指导组有39名,血管造影组的有33名。分析结果发现,移植失败率在两组

山东省发布分市心血管健康指数

从山东省卫健委获悉,近日,山东省卫生健康委员会、中国心血管健康联盟、中国疾病预防控制中心慢病中心联合在济南召开山东省心血管疾病防治工作座谈会。中国心血管健康联盟主席、中国科学院院士葛均波发布山东省17市心血管健康指数研究结果,山东省卫生健康委员会副主任、党组成员秦成勇做关于山东省心血管疾病防治策略的主旨讲话。

Baidu
map
Baidu
map
Baidu
map